Patient-Derived XenograftPDX Model Market Size, Growth | Industry Report, 2021-2027
The global Patient-Derived XenograftPDX Model market gathered revenue around USD 137 million in 2020 and market is set to grow USD 310 million by the end of 2027 and is estimated to expand at a modest CAGR of 18% during the prediction period 2021 to 2027. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Patient-Derived XenograftPDX Model market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Patient-Derived XenograftPDX Model market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Patient-Derived XenograftPDX Model market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
North America was the largest regional market for PDX models market in 2020.
Geographically, the PDX model market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2020, North America accounted for the largest share of the PDX models market, followed by Europe and the Asia Pacific. The large share of the North American market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Patient-Derived XenograftPDX Model Market are:
The PDX models market include JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Oncodesign (France), Charles River Laboratories (US), Hera Biolabs (US), EPO Berlin-Buch (Germany), Envigo (US), Xentech (France), Urosphere (France), and Explora BioLabs (US).
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
PDX models Market, by Type
PDX models Market, by Tumor Type
PDX models Market, by Application
PDX models Market, by End User
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Patient-Derived Xenograft/PDX Model Market, By Type
7.1. Patient-Derived Xenograft/PDX Model Market, by Type, 2021-2027
7.1.1. Mice Models
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Rat Models
7.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Patient-Derived Xenograft/PDX Model Market, By Tumor Type
8.1. Patient-Derived Xenograft/PDX Model Market, by Tumor Type, 2021-2027
8.1.1. Gastrointestinal Tumor Models
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Gynecological Tumor Models
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Respiratory Tumor Models
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Urological Tumor Models
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Hematological Tumor Models
8.1.5.1. Market Revenue and Forecast (2016-2027)
8.1.6. Other Tumor Models
8.1.6.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Patient-Derived Xenograft/PDX Model Market, By Application
9.1. Patient-Derived Xenograft/PDX Model Market, by Application, 2021-2027
9.1.1. Preclinical Drug Development
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Biomarker Analysis
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Basic Cancer Research
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Patient-Derived Xenograft/PDX Model Market, By End User
10.1. Patient-Derived Xenograft/PDX Model Market, by End User, 2021-2027
10.1.1. Pharmaceutical & Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Contract Research Organizations (CROs)
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 11.Global Patient-Derived Xenograft/PDX Model Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2016-2027)
11.1.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.1.3. Market Revenue and Forecast, by Application (2016-2027)
11.1.4. Market Revenue and Forecast, by End User (2016-2027)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Type (2016-2027)
11.1.5.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.1.5.3. Market Revenue and Forecast, by Application (2016-2027)
11.1.5.4. Market Revenue and Forecast, by End User (2016-2027)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Type (2016-2027)
11.1.6.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.1.6.3. Market Revenue and Forecast, by Application (2016-2027)
11.1.6.4. Market Revenue and Forecast, by End User (2016-2027)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2016-2027)
11.2.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.2.3. Market Revenue and Forecast, by Application (2016-2027)
11.2.4. Market Revenue and Forecast, by End User (2016-2027)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Type (2016-2027)
11.2.5.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.2.5.3. Market Revenue and Forecast, by Application (2016-2027)
11.2.5.4. Market Revenue and Forecast, by End User (2016-2027)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Type(2016-2027)
11.2.6.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.2.6.3. Market Revenue and Forecast, by Application (2016-2027)
11.2.6.4. Market Revenue and Forecast, by End User (2016-2027)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Type (2016-2027)
11.2.7.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.2.7.3. Market Revenue and Forecast, by Application (2016-2027)
11.2.7.4. Market Revenue and Forecast, by End User (2016-2027)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Type (2016-2027)
11.2.8.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.2.8.3. Market Revenue and Forecast, by Application (2016-2027)
11.2.8.4. Market Revenue and Forecast, by End User (2016-2027)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2016-2027)
11.3.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.3.3. Market Revenue and Forecast, by Application (2016-2027)
11.3.4. Market Revenue and Forecast, by End User (2016-2027)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Type (2016-2027)
11.3.5.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.3.5.3. Market Revenue and Forecast, by Application (2016-2027)
11.3.5.4. Market Revenue and Forecast, by End User (2016-2027)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Type (2016-2027)
11.3.6.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.3.6.3. Market Revenue and Forecast, by Application (2016-2027)
11.3.6.4. Market Revenue and Forecast, by End User (2016-2027)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Type (2016-2027)
11.3.7.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.3.7.3. Market Revenue and Forecast, by Application (2016-2027)
11.3.7.4. Market Revenue and Forecast, by End User (2016-2027)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Type (2016-2027)
11.3.8.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.3.8.3. Market Revenue and Forecast, by Application (2016-2027)
11.3.8.4. Market Revenue and Forecast, by End User (2016-2027)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2016-2027)
11.4.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.4.3. Market Revenue and Forecast, by Application (2016-2027)
11.4.4. Market Revenue and Forecast, by End User (2016-2027)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Type (2016-2027)
11.4.5.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.4.5.3. Market Revenue and Forecast, by Application (2016-2027)
11.4.5.4. Market Revenue and Forecast, by End User (2016-2027)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Type (2016-2027)
11.4.6.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.4.6.3. Market Revenue and Forecast, by Application (2016-2027)
11.4.6.4. Market Revenue and Forecast, by End User (2016-2027)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Type (2016-2027)
11.4.7.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.4.7.3. Market Revenue and Forecast, by Application (2016-2027)
11.4.7.4. Market Revenue and Forecast, by End User (2016-2027)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Type (2016-2027)
11.4.8.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.4.8.3. Market Revenue and Forecast, by Application (2016-2027)
11.4.8.4. Market Revenue and Forecast, by End User (2016-2027)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2016-2027)
11.5.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.5.3. Market Revenue and Forecast, by Application (2016-2027)
11.5.4. Market Revenue and Forecast, by End User (2016-2027)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Type (2016-2027)
11.5.5.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.5.5.3. Market Revenue and Forecast, by Application (2016-2027)
11.5.5.4. Market Revenue and Forecast, by End User (2016-2027)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Type (2016-2027)
11.5.6.2. Market Revenue and Forecast, by Tumor Type (2016-2027)
11.5.6.3. Market Revenue and Forecast, by Application (2016-2027)
11.5.6.4. Market Revenue and Forecast, by End User (2016-2027)
Chapter 12. Company Profiles
12.1. JSR Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. WuXi AppTec
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Champions Oncology, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. The Jackson Laboratory
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Oncodesign
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Charles River Laboratories
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Hera Biolabs
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. EPO Berlin-Buch
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Envigo
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Xentech
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers